Beone Medicines logo

Beone Medicines Share Price Today

(NASDAQ: ONC)

Beone Medicines share price is $267.39 & ₹22,848.74 as on 29 Mar 2025, 2.30 'hrs' IST

$267.39

4.79

(1.82%)

Market is closed - opens 7 PM, 31 Mar 2025

View live Beone Medicines share price in Dollar and Rupees. Guide to invest in Beone Medicines stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Beone Medicines, along with analyst recommendations, forecasts, and comprehensive financials.

Beone Medicines share price movements

  • Today's Low: $265.58
    Today's High: $273.94

    Day's Volatility :3.05%

  • 52 Weeks Low: $172.67
    52 Weeks High: $287.88

    52 Weeks Volatility :40.02%

Beone Medicines (ONC) Returns

PeriodBeone Medicines LtdIndex (Russel 2000)
3 Months
45.47%
0.0%
6 Months
19.1%
0.0%
1 Year
67.93%
0.0%
3 Years
41.78%
-15.4%

Beone Medicines (ONC) Key Statistics

in dollars & INR

Previous Close
$262.6
Open
$269.0
Today's High
$273.94
Today's Low
$265.58
Market Capitalization
$30.6B
Today's Volume
$514.6K
52 Week High
$287.88
52 Week Low
$172.67
Revenue TTM
$3.8B
EBITDA
$-402.0M
Earnings Per Share (EPS)
$-6.12
Profit Margin
-16.92%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-18.77%

How to invest in Beone Medicines Stock (ONC) from India?

It is very easy for Indian residents to invest directly in Beone Medicines from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Beone Medicines stock in both Indian Rupees (INR) and US Dollars (USD). Search for Beone Medicines or ONC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Beone Medicines or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Beone Medicines shares which would translate to 0.003 fractional shares of Beone Medicines as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Beone Medicines, in just a few clicks!

Returns in Beone Medicines (ONC) for Indian investors in Rupees

The Beone Medicines stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Beone Medicines investment value today

Current value as on today

₹1,70,465

Returns

₹70,465

(+70.46%)

Returns from Beone Medicines Stock

₹67,927 (+67.93%)

Dollar Returns

₹2,538 (+2.54%)

Indian investors sentiment towards Beone Medicines (ONC)

178%

Period: Feb 27, 2025 to Mar 29, 2025. Change in 30 Days versus previous period

Search interest for Beone Medicines Stock from India on INDmoney has increased by 178% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Beone Medicines

Analyst Forecast on Beone Medicines Stock (ONC)

What analysts predicted

Upside of 24.07%

Target:

$331.74

Current:

$267.39

Insights on Beone Medicines Stock (Ticker Symbol: ONC)

  • Price Movement

    In the last 7 days, ONC stock has moved up by 6.1%
  • ONC vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 79.6% return, outperforming this stock by 8.6%
  • ONC vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 62.5% return, outperforming this stock by 32.7%
  • Price to Sales

    Beone Medicines Ltd has a Price-to-Sales (P/S) Ratio of 7.4, meaning that investors are willing to pay $7.4 for every $1 of sales the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a higher P/S Ratio of 15.2, indicating that investors are willing to pay more for each dollar of sales compared to Beone Medicines Ltd.

Beone Medicines Technicals Summary

Sell

Neutral

Buy

Beone Medicines is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Beone Medicines (ONC) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beone Medicines Ltd logo
-1.62%
19.1%
67.93%
41.78%
117.2%
Regeneron Pharmaceuticals, Inc. logo
-8.78%
-39.37%
-34.25%
-8.74%
30.53%
Vertex Pharmaceuticals Incorporated logo
2.69%
5.94%
17.17%
88.79%
107.06%
Alnylam Pharmaceuticals, Inc. logo
8.8%
-2.39%
75.09%
64.41%
146.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beone Medicines Ltd logo
NA
NA
NA
1.45
-0.19
-0.06
NA
31.22
Regeneron Pharmaceuticals, Inc. logo
16.61
16.61
0.95
42.62
0.16
0.07
0.01
273.57
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.4
18.06
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.83
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beone Medicines Ltd logo
NA
$30.6B
117.2%
NA
-16.92%
Regeneron Pharmaceuticals, Inc. logo
Buy
$69.7B
30.53%
16.61
31.07%
Vertex Pharmaceuticals Incorporated logo
Buy
$126.5B
107.06%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$34.7B
146.63%
NA
-12.37%

About Beone Medicines

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Organization
Beone Medicines
Employees
11000
CEO
Mr. John V. Oyler
Industry
Miscellaneous

Management People of Beone Medicines

NameTitle
Mr. John V. Oyler
Co-Founder, Executive Chairman & CEO
Dr. Xiaobin Wu Ph.D.
President & COO
Dr. Xiaodong Wang Ph.D.
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder
Mr. Chan Lee
General Counsel & Senior VP
Mr. Wang Lai Ph.D.
Global Head of R&D
Mr. Aaron Rosenberg
CFO & Principal Financial Officer
Mr. Titus B. Ball
VP & Chief Accounting Officer
Ms. Liza Heapes
Head of Investor Relations
Mr. Yang Ji
Chief Compliance Officer
Dr. Yan Qi
Senior VP & Head of Public Affairs - Greater China

Important FAQs about investing in ONC Stock from India :

What is Beone Medicines share price today?

Beone Medicines share price today stands at $267.39, Open: $269.00 ; Previous Close: $262.60 ; High: $273.94 ; Low: $265.58 ; 52 Week High: $287.88 ; 52 Week Low: $172.67.

The stock opens at $269.00, after a previous close of $262.60. The stock reached a daily high of $273.94 and a low of $265.58, with a 52-week high of $287.88 and a 52-week low of $172.67.

Can Indians buy Beone Medicines shares?

Yes, Indians can invest in the Beone Medicines (ONC) from India.

With INDmoney, you can buy Beone Medicines at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Beone Medicines at zero transaction cost.

How can I buy Beone Medicines shares from India?

It is very easy to buy Beone Medicines from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Beone Medicines (ONC) be purchased?

Yes, you can buy fractional shares of Beone Medicines with INDmoney app.

What are the documents required to start investing in Beone Medicines stocks?

To start investing in Beone Medicines, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Beone Medicines Stock (ONC)?

Today’s highest price of Beone Medicines (ONC) is $273.94.

Today’s lowest price of Beone Medicines (ONC) is $265.58.

What is today's market capitalisation of Beone Medicines?

Today's market capitalisation of Beone Medicines ONC is 30.6B

What is the 52 Week High and Low Range of Beone Medicines Stock (ONC)?

  • 52 Week High

    $287.88

  • 52 Week Low

    $172.67

What are the historical returns of Beone Medicines (ONC)?

  • 1 Month Returns

    -1.62%

  • 3 Months Returns

    19.1%

  • 1 Year Returns

    67.93%

  • 5 Years Returns

    117.2%

Who is the Chief Executive Officer (CEO) of Beone Medicines ?

Mr. John V. Oyler is the current Chief Executive Officer (CEO) of Beone Medicines.